Anti-neutrophil cytoplasmic antibody-associated vasculitis, large vessel vasculitis and kawasaki disease in Japan

Kidney and Blood Pressure Research

Volumn 33, Issue 6, 2010, Pages 442-455

  Kobayashi, Shigeto ^a   Fujimoto, Shouichi ^b   Takahashi, Kei ^c   Suzuki, Kazuo ^d  

^a Juntendo University Hospital   (Japan)

^b UNIVERSITY OF MIYAZAKI HOSPITAL   (Japan)

^c TOHO UNIVERSITY OHASHI MEDICAL CENTER   (Japan)

^d CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Anti neutrophil cytoplasmic antibody; Epitope analysis; Epitopes; Kawasaki disease; Microscopic polyangiitis; Myeloperoxidase; Rapidly progressive glomerulonephritis; Systemic vasculitis; Vasculitis

Indexed keywords

CYCLOPHOSPHAMIDE; GLUCOCORTICOID; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISOLONE;

ANCA ASSOCIATED VASCULITIS; CHILD; CLINICAL FEATURE; DRUG DOSE REDUCTION; DRUG MEGADOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENOTYPE; GIANT CELL ARTERITIS; HUMAN; JAPAN; JAPANESE; MUCOCUTANEOUS LYMPH NODE SYNDROME; NONHUMAN; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS; RENOVASCULAR DISEASE; REVIEW; SYSTEMIC VASCULITIS; WEGENER GRANULOMATOSIS;

ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ARTERITIS; CHURG-STRAUSS SYNDROME; HUMANS; JAPAN; MUCOCUTANEOUS LYMPH NODE SYNDROME; VASCULITIS; WEGENER GRANULOMATOSIS;

EID: 78149317304     PISSN: 14204096     EISSN: None     Source Type: Journal    
DOI: 10.1159/000320383     Document Type: Review

References (79)

1. Takagi D, Nakamaru Y, Maguchi S, Furuta Y, Fukuda S: Otologic manifestations of Wegener's granulomatosis. Laryngoscope 2002; 112: 1684-1690.
2. Fujimoto S, Uezono S, Hisanaga S, Fukudome K, Kobayashi S, Suzuki K, et al: Incidence of ANCA-associated primary real vasculitis in the Miyazaki Prefecture: the first population based, retrospective, epidemiological survey in Japan. Clin J Am Soc Nephrol 2006; 1: 1016-1022.
3. Watts RA, Scott DGI, Jayne DRW, Suzuki K, Hashimoto H: A comparative study of the diagnostic accuracy of ELISA systems for the detection of anti-neutrophil cytoplasm antibodies available in Japan and Europe. Clin Exp Rheumatol 2008; 26: 1027-1033.
4. Watts RA, Gonzalez-Gay MA, Lane SE, Garcia-Porrua, Bentham G, Scott DG: Geoepidemilogy of systemic vasculitis: comparison of the incidence in two regions of Europe. Ann Rheum Dis 2001; 60: 170-172.
5. Kobayashi S, Yano T, Matsumoto Y, Numano F, Nakajima N, Yasuda K, Yutani C, Nakayama T, Tamakoshi A, Kawamura T, Ohno Y, Inaba Y, Hashimoto H: Clinical and epidemiologic analysis of giant cell (temporal) arteritis from a nationwide survey in 1998 in Japan: the first government-supported nationwide survey. Arthritis Rheum 2003; 49: 594-598.
6. Watts RA, Scott DG, Jayne DR, Ito-Ihara T, Muso E, Fujimoto S, Harabuchi Y, Kobayashi S, Suzuki K, Hashimoto H: Renal vasculitis in Japan and the UK-are there differences in epidemiology and clinical phenotype? Nephrol Dial Transplant 2008; 23: 3928-3931.
7. Nakamaru Y, Maguchi S, Takizawa M, Fukuda S, Inuyama Y: The association between human leukocyte antigens (HLA) and cytoplasmic-antineutrophil cytoplasmic antibody (cANCA)-positive Wegener's granulomatosis in a Japanese population. Rhinology 1996; 34: 163-165.
8. Seta N, Tajima M, Kobayashi S, Kawakami Y, Hashimoto H, Kuwana M: Autoreactive Tcell responses to myeloperoxidase in patients with antineutrophil cytoplasmic antibodyassociated vasculitis and in healthy individuals. Mod Rheumatol 2008; 18: 593-600.
9. Fujii A, Tomizawa K, Arimura Y, Nagasawa T, Y-Ohashi Y, Hiyama T, Mizuno S, Suzuki K: Epitope analysis of myeloperoxidase-specific anti-neutrophil cytoplasmic antibody (MPO-ANCA) associated glomerulonephritis. Clin Nephrol 2000; 53: 242-252.
10. Arimura Y, Minoshima S, Kamiya Y, Tanaka U, Nakabayashi K, Kitamoto K, Nagasawa T, Sasaki T, Suzuki K: Serum myeloperoxidase and serum cytokines in anti-myeloperoxidase antibody-associated glomerulonephritis. Clin Nephrol 1993; 40: 256-264.
11. Tomizawa K, Mine E, Fujii A, Ohashi Y, Yamagoe S, Ishida-Okawara A, Hashimoto Y, Ito M, Tanokura M, Yamamoto T, Arimura Y, Nagasawa T, Mizuno S, Suzuki K: A panel set for epitope analysis of myeloperoxidase (MPO)-specific anti-neutrophil cytoplasmic antibody MPO-ANCA using recombinant hexamer histidine-tagged MPO del etion mutants. J Clin Immunol 1998; 18: 142-152.
12. Erdbrügger U, Hellmark T, Bunch DO, Alcorta1 DA, Jennette JC, Falk RJ, Nachman PH: Mapping of myeloperoxidase epitopes recognized by MPO-ANCA using humanmice MPO chimeras. Kidney Int 2006; 69: 1799-805.
13. van der Geld YM, Stegman CA, Kallenberg CGM: B cell epitope specificity in ANCAassociated vasculitis: does it matter? Clin Exp Immunol 2004; 137: 451-459.
14. Van der Geld YM, Huitema MG, Franssen CF, van der Zee R, Limburg PC, Kallenberg CGM: In vitro T lymphocyte responses to proteinase 3 (PR3) and linear peptides of PR3 in patients with Wegener's granulomatosis (WG). Clin Exp Immunol 2000; 122: 504-513.
15. Ito-Ihara T, Muso E, Kobayashi S, Uno K, Tamura N, Yamanishi Y, Fukatsu A, Watts RA, Scott DGI, Jayne DRW, Suzuki K, Hashimoto H: A comparative study of the diagnostic accuracy of ELISA for the detection of anti-neutrophil cytoplasma antibodies available in Japan and Europe. Clin Exp Rheum 2008; 26: 1027-1033.
16. Nakamura Y, Yashiro M, Uehara R, et al: Epidemiologic features of Kawasaki disease in Japan: results of the 2007-2008 nationwide survey. J Epidemiol 2010; 20: 302-307.
17. Wu MH, Nakamura Y, Burns J, et al: Stateof-the-art basic and clinical science of Kawasaki disease. Pediatric Health 2008; 2: 405-409.
18. Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, Hagen EC, Hoffman GS, Hunder GG, Kallenberg CG, et al: Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994; 37: 187-192.
19. Weidner N: Giant-cell vasculitides. Semin Diagn Pathol 2001; 18: 24-33.
20. Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH, Heyse SP, Hirsch R, Hochberg MC, Hunder GG, Liang MH, Pillemer SR, Steen VD, Wolfe F: Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998; 41: 778-799.
21. González-Gay MA, Alonso MD, Agüero JJ, Bal M, Fernández-Camblor B, Sánchez-Andrade A: Temporal arteritis in a northwestern area of Spain: study of 57 biopsy proven patients. J Rheumatol 1992; 19: 277-280.
22. Yamaguchi A, Ogawa A, Tsuchiya N, Shiota M, Mitsui H, Tokunaga K, Tadokoro K, Juji T, Ito K: HLA-B27 subtypes in Japanese with seronegative spondyloarthropathies and healthy controls. J Rheumatol 1996; 23: 1189-1193.
23. Numano F: Differences in clinical presentation and outcome in different countries for Takayasu's arteritis. Curr Opin Rheumatol 1997; 9: 12-15.
24. Chen M, Yu F, Zhang Y, Zou WZ, Zhao MH, Wang HY: Characteristics of Chinese patients with Wegener's granulomatosis with anti-myeloperoxidase autoantibodies. Kidney Int 2005; 68: 2225-2229.
25. Kobayashi S, Yano T, Inaba Y, Hashimoto H, Matsumoto Y, Tamakoshi A, et al: Ocular involvements of Japanese patients with giant cell arteritis from the first nation-wide study. Arthritis Rheum 2003; 49: 867-868.
26. Tsuzuki K, Fukazawa K, Takebayashi H, Hashimoto K, Sakagami M: Difficulty of diagnosing Wegener's granulomatosis in the head and neck region. Auris Nasus Larynx 2009; 36: 64-70.
27. Hoffman GS, Kerr GS, Leavbitt RY, Hallahan CW, Lebovics RS, Travis W, et al: Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992; 116: 488-498.
28. Tsuchiya N, Kobayashi S, Kawasaki A, Kyogoku C, Arimura Y, Yoshida M, Tokunaga K, Hashimoto H: Genetic background of Japanese patients with antineutrophily cytoplasmic antibody-associated vasculitis: association of HLA-DRB1 * 0901 with microscopic polyangiitis. J Rheumatol 2003; 30: 1534-1540.
29. Mamegano K, Kuroki K, Miyashita R, Kusaoi M, Kobayashi S, Matsuta K, Maenaka K, Colonna M, Ozaki S, Hashimoto H, Takasaki Y, Tokunaga K, Tsuchiya N: Association of LILRA2 (ILT1, LIR7) splice site polymorphism with systemic lupus erythematosus and microscopic polyangiitis. Genes Immun 2008; 9: 214-223.
30. Miyashita R, Tsuchiya N, Yabe T, Kobayashi S, Hashimoto H, Ozaki S, Tokunaga K: Association of killer cell immunoglobulin-like receptor genotypes with microscopic polyangiitis. Arthritis Rheum 2006; 54: 992-997.
31. Tsuchiya N, Kobayashi S, Hashimoto H, Ozaki S, Tokunaga K: Association of HLADRB1 * 0901-DQB1 * 0303 haplotype with microscopic polyangiitis in Japanese. Genes Immun 2006; 7: 81-84.
32. Jayne DRW; European Vasculitis Study Group (EUVAS): Update on the European Vasculitis Study Group trials. Curr Opin Rheumatol 2001; 13: 48-55.
33. Koyama A, Yamagata K, Makino H, Arimura Y, Wada T, Nitta K, Nihei H, Muso M, Taguma Y, Shigematsu H, Sakai H, Tomino Y, Matsuo S, Japan RPGN Registry Group: A nationwide surveillance of rapidly progressive glomerulonephritis in Japan; etiology, prognosis and treatment diversity. Clin Exp Nephrol 2009; 13: 633-650.
34. Hogan SL, Nachman PH, Wilkman AS, JC Jennette JC, Falk RJ: Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 1996; 7: 23-32.
35. Hauer HA, Bajema IM, Van Houwelingen HC, Ferrario F, Noël LH, Waldherr R, Jayne DRW, Rasmussen N, Bruijn JA, Hagen EC, European Vasculitis Study Group (EUVAS): Renal histology in ANCA-associated vasculitis: differences between diagnostic and serologic subgroups. Kidney Int 2002; 61: 80-89.
36. Tidman M, Olamder R, Avalander C, Danielsson D: Patients hospitalized because of small vessel vasculitides with renal involvement in the period 1975-1955: organ involvement, ANCA patterns, seasonal attack rates and fluctuation of annual frequencies. J Intern Med 1988; 244: 133-141.
37. Booth AD, Almond MK, Burns A, Ellis P, Gaskin G, Neild GH, Plaisance M, Pusey CD, Jayne DRW: Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis 2003; 41: 776-784.
38. Matsumoto M, Kobayashi S, Hashimoto H, et al: Nationwide epidemiological survey of refractory vasculitis (anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, anti-phospholipid syndrome and temporal arteritis) in Japan. Annual report of the Research Committee on Intractable Vasculitides, the Ministry of Health and Welfare of Japan,1998, pp 15-23 (in Japanese).
39. Sakai K, Kurokawa K, Koyama A, et al: Committee for the Guidelines on Diagnosis and Therapy of Rapidly Progressive Glomerulonephritis: the guidelines for the management of rapidly progressive glomerulonephritis (in Japanese). Jpn J Nephrol 2002; 44: 55-83.
40. Usui J, Yamagata K: Present status and future perspective of RPGN in Japan (in Japanese). Jpn J Nephrol 2009; 51: 78-83.
41. Lane SE, Scott DG, Heaton A, Watts RA: Primary renal vasculitis in Norfolk-increasing incidence or increasing recognition? Nephrol Dial Transplant 2000; 15: 23-27.
42. Satchell SC, Nicholls AJ, D'Souza RJ, Beaman M: Renal vasculitis: increasing a disease of the elderly? Nephron Clin Prac 2004; 97:c142-c146.
43. Uezono S, Sato Y, Hara S, Hisanaga S, Fukudome K, Fujimoto S, Nakao H, Kitamura K, Kobayashi S, Suzuki K, Hashimoto H, Nunoi H: Outcome of ANCA-associated primary renal vasculitis in Miyazaki Prefecture. Intern Med 2007; 46: 815-822.
44. Jayne D: Progress of treatment in ANCA-associated vasculitis. Nephrology 2009; 14: 42-48.
45. Suzuki K, Kobayashi S, Yamazaki K, Gondo M, Tomizawa K, Arimura Y, Nakabayashi K, Ozaki S, Yoshida M, Yoshida T, Tsusaka N, Muso E, Okazaki T, Hashimoto H: Analysis of risk epitopes of anti-neutrophil antibody MPO-ANCA in vasculitis in Japan population. Microbiol Immunol 2007; 51: 1215-1220.
46. Falk RJ, Jennette JC: ANCA are pathogenic-oh yes they are! J Am Soc Nephrol 2002; 13: 1977-1979.
47. Heeringa ]P, Tervaert JWC: Pathophysiology of ANCA-associated vasculitides: are ANCA really pathogenic? Kidney Int 2004; 65: 1564-1567.
48. Suzuki R, Tomizawa K, Suzuki K, Tanokura M: MPO-ANCA Binding site on MPO molecule estimated from epitope mapping study and molecular modeling. Bioimages 2004; 12: 85-90.
49. Holle JU, Hellmich B, Backes M, Gross WL, Csernok E: Variations in performance characteristics of commercial enzyme immunoassay kits for detection of antineutrophil cytoplasmic antibodies: what is the optimal cut off? Ann Rheum Dis 2005; 64: 1773-1779.
50. Trevisin M, Pollock W, Dimech W, et al: Antigen-specific ANCA ELISAs have different sensitivities for active and treated vasculitis and for nonvasculitic disease. Am J Clin Pathol 2008; 129: 42-53.
51. Hagen EC, Andrassy K, Chernok E, et al: The value of indirect immunofluorescence and solid phase techniques for ANCA detection. A report on the first phase of an international cooperative study on the standardization of ANCA assays. EEC/BCR Group for ANCA Assay Standardization. J Immunol Methods 1993; 159: 1-16.
52. Pollock W, Dunster K, Rolland JM, Koh H, Savige J: A comparison of commercial and in-house ELISAs for antineutrophil cytoplasmic antibodies directed against proteinase 3 and myeloperoxidase. Pathology 1999; 31: 38-43.
53. Kobayashi S, Ito A, Okuzaki D, Onda H, Yabuta N, Nagamori I, Suzuki K, Hashimoto H, Nojima H: Expression profiling of PBMCbased diagnostic gene markers isolated from vasculitis patients. DNA Res 2008; 15: 253-265.
54. Tougan T, Onda H, Okuzaki D, Kobayashi S, Hashimoto H, Nojima H: Focused microarray analysis of peripheral mononuclear blood cells from Churg-Strauss syndrome patients. DNA Res 2008; 15: 103-114.
55. Kinjoh K, Kyogoku M, Good RA: Genetic selection for crescent formation yields mouse strain with rapidly progressive glomerulonephritis and small vessel vasculitis. Proc Natl Acad Sci USA 1993; 90: 3413-3417.
56. Neumann I, Birck R, Newman M, Schnülle P, Kriz W, Nemoto K, Yard B, Waldherr R, Van Der Woude FJ: SCG/Kinjoh mice: a model of ANCA-associated crescentic glomerulonephritis with immune deposits. Kidney Int 2003; 64: 140-148.
57. Ishida-Okawara A, Ito-Ihara T, Muso E, Ono T, Saiga K, Nemoto K, Suzuki K: Neutrophil contribution to the crescentic glomerulonephritis in SCG/Kj mice. Nephrol Dial Transplant 2004; 19: 1708-1715.
58. Jethwa HS, Clarke SH, Itoh-Lindstrom Y, Falk RJ, Jennette JC, Nachman PH: Restriction in V kappa gene use and antigen selection in anti-myeloperoxidase response in mice. J Immunol 2000; 165: 3890-3897.
59. Hamano Y, Tsukamoto K, Abe M, Sun GD, Zhang D, Fujii H, Matsuoka S, Tanaka M, Ishida-Okawara A, Tachikawa H, Nishimura H, Tokunaka K, Hirose S, Suzuki K: Genetic dissection of vasculitis, myeloperoxidasespecific antineutrophil cytoplasmic autoantibody production, and related traits in spontaneous crescentic glomerulonephritisforming/ Kinjoh mice. J Immunol 2006; 176: 3662-3673.
60. Kawasaki T: Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of fingers and toes in children. Clinical observation of 50 patients (in Japanese). Jpn J Allergy 1967; 16: 178-222.
61. Kawasaki T, Kosaki F, Okawa S, et al: A new infantile acute febrile mucocutaneous lymph-node syndrome (MLNS) prevailing in Japan. Pediatrics 1974; 54: 271-276.
62. Ayusawa M, Sonobe T, Uemura S, et al, Kawasaki Disease Research Committee: Revision of diagnostic guidelines for Kawasaki disease (the 5th revised edition). Pediatr Int 2005; 47: 232-234.
63. Masuda H, Naoe S, Tanaka N: A pathological study of coronary artery in Kawasaki disease (MCLS)-with special reference to morphogenesis of aneurysm (in Japanese). J Jpn Coll Angiol 1981; 21: 899-912.
64. Landing HL, Larson E: Pathological features of Kawasaki disease (mucocutaneous lymph node syndrome). Am J Cardiovasc Pathol 1987; 1: 215-229.
65. Takahashi K, Oharaseki T, Naoe S, et al: Neutrophilic involvement in the damage to coronary arteries in acute stage of Kawasaki disease. Pediatr Int 2005; 47: 305-310.
66. Takahashi K, Oharaseki T, Naoe S: Pathological study of postcoronary arteritis in adolescents and young adults, with reference to the relationship between sequelae of Kawasaki disease and atherosclerosis. Pediatr Cardiol 2001; 22: 138-142.
67. Furusho K, Kamiya T, Nakano H, et al: Highdose intravenous gamma globulin for Kawasaki disease. Lancet 1984; 2: 1055-1058.
68. Newburger JW, Takahashi M, Burns JC, et al: The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 1986; 315: 341-347.
69. Newburger JW, Sleeper LA, McCrindle BW, et al, Pediatric Heart Network Investigators: Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N Engl J Med 2007; 356: 663-675.
70. Inoue Y, Okada Y, Shinohara M, et al: A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease: clinical course and coronary artery outcome. J Pediatr 2006; 149: 336-341.
71. Nakano M, Yamada S. Hayashi Y, et al: Preventive effects of ulinastatin for coronary artery aneurysm formation in Kawasaki Disease; in Kato H (ed): Kawasaki Disease. Amsterdam, Elsevier Science, 1995, pp 364-371.
72. Mori M, Imagawa T, Katakura S, et al: Efficacy of plasma exchange therapy for Kawasaki disease intractable to intravenous gamma-globulin. Mod Rheumatol 2004; 14: 43-47. (Pubitemid 40796159)
73. Burns JC, Mason WH, Hauger SB, et al: Infliximab treatment for refractory Kawasaki syndrome. J Pediatr 2005; 146: 662-667.
74. Murata H, Naoe S: Experimental Candidainduced arteritis in mice-relation to arteritis in Kawasaki disease. Prog Clin Biol Res 1987; 250: 523.
75. Lehman TJ, Warren R, Gietl D, et al: Variable expression of Lactobacillus casei cell wallinduced coronary arteritis: an animal model of Kawasaki's disease in selected inbred mouse strains. Clin Immunol Immunopathol 1988; 48: 108-118.
76. Philip S, Lee WC, Liu SK, et al: A swine model of horse serum-induced coronary vasculitis: an implication for Kawasaki disease. Pediatr Res 2004; 55: 211-219.
77. Oharaseki T, Kameoka Y, Kura F, Persad AS, Suzuki K, Naoe S: Susceptibility loci to coronary arteritis in animal model of Kawasaki disease induced with Candida albicans-derived substances. Microbiol Immunol 2005; 49: 181-189.
78. Nagai-Miura N, Shingo Y, Adachi Y, Ishida-Okawara A, Oharaseki T, Takahashi K, Naoe S, Suzuki K, Ohno N: Induction of coronary arteritis with administration of CAWS ( Candida albicans water-soluble fraction) depending on mouse strains. Immunopharmacol Immunotoxicol 2004; 26: 527-543.
79. Takahashi K, Oharaseki T, Yokouchi Y, Miura NN, Ohno N, Okawara AI, Murata H, Naoe S, Suzuki K: Administration of human immunoglobulin suppresses development of murine systemic vasculitis induced with Candida albicans water-soluble fraction: an animal model of Kawasaki disease. Mod Rheumatol 2010; 20: 160-167.